Our CEO, Dr James Garner was interviewed in BioWorld on the recent release of interim efficacy data from the phase II trial of GDC-0084 in glioblastoma as well as the overall GDC-0084 program.
Our Chief Executive Officer, Dr James Garner, sat down with Stuart Roberts of Pitt Street Research in Sydney to discuss the company’s recent announcement of positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma.
Kazia is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2019 AGM, together with questions and answers relating to the presentation.
Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia
Which of the following group do you best fit?
Subscribe to our Email Alerts